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Abstract
For greater than a decade, methotrexate has been known to be an effective therapeutic agent in the 
treatment of steroid dependent active Crohn's disease. However, international data on medication 
utilization suggest that this drug is rarely used in clinical practice for an indication of Crohn's 
disease. This review investigates the potential reasons for the underuse of methotrexate in patients 
with inflammatory bowel diseases.
Introduction
Analyses of the volume of prescriptions for methotrexate reveal that methotrexate is 
prescribed in a negligible quantity when compared to other drugs used in the treatment of 
inflammatory bowel diseases (IBD), such as biologic anti-tumor necrosis factor-alpha (anti-
TNF) agents or thiopurines. We used data from LifeLink™ Health Plan Claims Database 
(IMS Health, Norwalk, CT) from 1997 through 2009, to calculate the number of 
prescriptions per 100,000 person-months by year in a cohort of over 100,000 individuals 
with IBD. Methotrexate use was negligible when compared to other immunosuppressive 
medications (Figure 1). In international studies of medication utilization in pediatric and 
elderly populations, methotrexate utilization in IBD has also been shown to be lower than 
that of other medications, such as biologic anti-TNF agents. By comparison, Canadian 
methotrexate use is somewhat higher than that of other European countries and the US, but 
overall use remains low 1–3. Yet, methotrexate, which was initially developed in 1948 for 
the treatment of leukemia, has a successful track record in the treatment of autoimmune and 
neoplastic diseases. Moreover, for nearly 60 years it has been used clinically as low and high 
dose therapy to treat lymphomas, Wegener's disease, psoriasis and rheumatoid arthritis. We 
will explore the possible rationale for low utilization of methotrexate in IBD, including 
effectiveness compared to other available drugs, toxicity, costs, patient preference and 
recommendations by current treatment guidelines.
Efficacy of methotrexate in Crohn's disease and ulcerative colitis
The clinical efficacy of methotrexate has been well established for steroid dependent 
Crohn's disease (CD) in adults. The first report by Kozarek et al. in 1989 described 21 
patients (14 with CD, 7 with ulcerative colitis (UC)), who were treated with 25 mg 
methotrexate intramuscularly (im) 4. The outcome of this “therapeutic experiment” was very 
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encouraging with the majority of the patients (16 of the 21) reporting improvement of their 
symptoms. Based on this initial experience the North American Crohn's study group 
performed a landmark trial in patients with steroid dependent CD. At the end of 16 weeks 
significantly more patients receiving methotrexate (25 mg im /week) were in clinical 
remission compared to patients treated with placebo (39% vs 19%, p< 0.03) 5. To 
compensate for the delayed onset of action of methotrexate of 6–8 weeks all patients in the 
trial underwent a 12-week steroid-tapering schedule. Sixty-five% of the patients, who 
entered remission after 16 to 24 weeks of treatment with methotrexate (25 mg/im/once 
weekly), stayed in remission on 15 mg/ im /once weekly for over 40 weeks compared to 
39% on placebo (p<0.04) 6. Subsequently several uncontrolled observations in adults and 
children similarly reported the effectiveness of methotrexate in CD patients, who did not 
respond or did not tolerate thiopurines 7–10. Methotrexate also seems to have some efficacy 
in treating fistulizing Crohn's disease 9, 11.
Conversely, there were also two smaller placebo controlled trials published in 1997 and 
1999 after the initial successful North American Crohn's study group trial (2 and 4 years 
respectively), which failed to show any significant effectiveness of methotrexate compared 
to placebo 12, 13. These 2 studies may serve as prime examples of factors that can potentially 
influence methotrexate effectiveness in patients with IBD, including dosing and method of 
application. Both studies used oral methotrexate at doses of either 12.5 mg once weekly or 
15 mg once weekly. Knowledge of a dose-response for methotrexate therapy is well 
established in rheumatoid arthritis (RA), psoriasis and also in a small trial of IBD patients, 
demonstrating that higher doses of around 25 mg once weekly may be essential to control 
the inflammatory activity in patients with IBD 14–18.
Methotrexate, if given orally, is absorbed in the proximal jejunum. The exact process of 
absorption is not yet elucidated. Thus, in patients with small bowel CD, absorption and the 
ensuing bioavailability of methotrexate may be reduced. Oral methotrexate most likely 
reaches sufficient bioavailability at a dose below 15 mg, however above this threshold 
absorption rates and thus the bioavailability can decrease by 30%–70% 19–22. The difference 
between oral and subcutaneous (sc) application with regard to clinical effectiveness has been 
elegantly demonstrated in a study by Braun et al, which confirmed a significantly higher 
efficacy of 15 mg methotrexate when applied as an sc injection once weekly than to the 
same dose taken orally once weekly 23.
The clinical value of methotrexate in UC is currently being debated. The only prospective 
placebo controlled trial in patients with steroid dependent UC did not reveal significant 
differences in the clinical outcome between oral methotrexate (12.5 mg/week) and 
placebo 24. However, several case series suggest that methotrexate could be similarly 
effective in patients with UC as in CD if methotrexate is administered by a method (sc or 
im) and dosage (25 mg/week) analogous to that utilized in the North American Crohn's 
study (reviewed by Herfarth et al in 2010 and Carbonnel in 2011 25, 26).
Two clinical trials are underway to finally prove or refute the efficacy of methotrexate in 
UC. An investigator-initiated trial in France titled “Comparison of Methotrexate vs Placebo 
in Steroid-Refractory Ulcerative Colitis (acronym: METEOR)“ is currently investigating the 
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effectiveness of methotrexate (25 mg /week/sc) compared to placebo in inducing steroid-free 
remission in steroid-dependent ulcerative colitis (www.ClinicalTrials.gov; NCT00498589). 
The second clinical trial started in February 2012 and is recruiting patients in the US (figure 
2). This randomized, double blind, prospective trial (MEthotrexate Response In Treatment 
of Ulcerative Colitis; acronym: Merit-UC) investigates the ability of methotrexate to induce 
and maintain steroid-free remission in patients with UC (www.ClinicalTrials.gov; 
NCT01393405). Hopefully both of these trials will help to further elucidate the efficacy of 
methotrexate in patients with active UC in need for an effective and affordable steroid-
sparing agent.
Efficacy of methotrexate compared to azathioprine
Cochrane analyses pertaining to the ability of azathioprine/6-mercaptopurine (6-MP) or 
methotrexate in inducing and maintaining remission in patients with steroid-dependent CD 
reveal similar efficacies for both therapies for the number of patients needed to be treated to 
achieve and maintain remission (table 1) 27–30. Only a few small direct comparative studies 
exist in IBD aiming to compare the clinical value of methotrexate with that of azathioprine 
or 6-MP. In a study by Mate-Jimenez et al., which included steroid-dependent patients with 
CD (n=34) or ulcerative colitis (n=38), 79% of patients randomized to 6-MP (1.5mg/kg day) 
were in remission after 30 weeks compared to 58% of patients on methotrexate (15mg/week/ 
oral) 31. No significant differences in the rate of remission and steroid sparing were found in 
patients with steroid-dependent CD (n=54) assigned either to methotrexate or azathioprine 
(figure 3) 32. An Israeli multicenter trial comparing the efficacy of 12.5 mg methotrexate 
(n=26), 50 mg 6-MP (n=32) or placebo (n=26) in patients with steroid-dependent CD over a 
9 months period found that neither treatment was better than placebo 13. However, in this 
trial neither methotrexate nor 6-MP were given in an optimal dose or route of 
administration.
Toxicity - adverse effects (AE) of methotrexate therapy
AE's of low-dose methotrexate therapy most often affect the gastrointestinal tract and 
include nausea, anorexia and less often stomatitis or diarrhea. More serious AE's include 
hepatotoxicity, bone marrow suppression33 and rarely hypersensitivity pneumonitis and 
opportunistic infections can occur 34. Since the majority of the drug is eliminated unchanged 
via the kidneys, toxicity of methotrexate in patients with impaired kidney function or 
dehydration is increased 35. Of note, so far no increased risk for lymphoma or other 
neoplasms has been described in patients on long-term methotrexate therapy 36, 37.
One major concern is the development of liver fibrosis and cirrhosis. Known factors 
associated with hepatotoxicity in patients treated with methotrexate are alcohol 
consumption, obesity, diabetes mellitus and viral hepatitis 36, 38. However, the overall 
perception of an increased risk of liver cirrhosis due to methotrexate therapy is probably 
based on the reported high incidences (greater than 20%) of liver fibrosis and cirrhosis in 
patients with psoriasis on methotrexate therapy 39. The exact mechanism for this high rate is 
not completely clarified, but one major factor of methotrexate-induced hepatotoxicity, aside 
the above-mentioned comorbidities, is the frequency of administration 40. Low dosages 
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given daily or on alternate days, as was initially performed in patients with psoriasis, results 
in a significant increase in the incidence of fibrosis or cirrhosis compared to larger doses 
given once weekly. This is probably due to an increased accumulation of toxic methotrexate 
metabolites in the liver, which most likely are insufficiently cleared with more frequent drug 
administration. In the setting of once weekly administrations the overall incidence of liver 
fibrosis seems to be very low in patients with rheumatoid arthritis and IBD. Kremer reports 
only 2 cases of liver cirrhosis in 719 patients with rheumatoid arthritis undergoing liver 
biopsies 41. Several studies in patients with IBD with cumulative dosages of methotrexate of 
up to 2.5 gram did not demonstrate liver cirrhosis on biopsy 8, 42–44.
A more common AE is the elevation of the liver enzymes aspartate transaminase (AST) 
and/or alanine transaminase (ALT). In the initial trial in patients with steroid-dependent CD, 
the elevation of these liver enzymes led to the withdrawal of 7% (7/94) of patients in the 
first 16 weeks of therapy with 25 mg methotrexate/week/im. 5. In the long-term study with 
maintenance therapy of 15 mg methotrexate/week/im no further patients had to be 
withdrawn because of liver toxicity 6.
The occurrence of drug-associated AE leading to the withdrawal of patients in the head to 
head trials of azathioprine/6-MP and methotrexate appears to be similar. In the largest trial 
by Ardizzone et al., 11% (6/54) of patients treated with azathioprine 2 mg/kg/day for 6 
months or 25 mg methotrexate/week (initially intravenous for 3 months, then oral 
application) 32 had to be withdrawn from drug treatment due to a drug associated AE. 
Reasons for withdrawal in the azathioprine group were fever, pancreatitis or hepatitis. For 
the methotrexate group, withdrawals occurred due to thrombocytopenia, leukopenia and 
hepatitis.
Cost and patient preference
Known drug adverse effects, clinical effectiveness and drug-associated costs drive patient's 
therapy preferences. Methotrexate is one of the most affordable immunosuppressive drugs in 
the current armamentarium of IBD therapy 45, 46. Even taking into account the generally 
recommended repeated measurements of CBC and LFTs every 4–8 weeks, it is highly cost 
effective. However, due to the need for weekly self-injections, patients might object to 
methotrexate if given a choice of an oral medication such as azathioprine compared to the 
injection with methotrexate (figure 4) 47. Additionally the need for vigorous birth control 
due to the teratogenicity of methotrexate might deter younger female patients. In fact 
methotrexate is the only drug with an absolute contraindication for pregnancy and breast-
feeding compared to all other medications used in IBD 48. Of note, a multi-national evidence 
based recommendation on the use of methotrexate in rheumatic disorders currently counsels 
also male patients that methotrexate therapy should be stopped 3 months before a planned 
pregnancy 14. This advice is based mainly on expert opinion and not on reliable clinical 
data. There are controversial reports of sterility in males on methotrexate mostly in the 
setting of chemotherapy, but there are no available studies, which evaluated the effect of 
methotrexate for men on miscarriages/birth defects or on newborns 49.
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In Europe, methotrexate is recommended as a second or third line immunosuppressive 
regimen in the current treatment guidelines 50. The guidelines currently state “…but at 
present, methotrexate is generally reserved for treatment of active or relapsing CD in those 
refractory to or intolerant of thiopurines or anti-TNF agents.” This recommendation is 
interesting, since the use of methotrexate in this scenario has not been evaluated in 
prospective clinical trials. Treatment recommendations from the US do not explicitly advise 
a preference for azathioprine/6-MP over methotrexate, rather acknowledge that more dose 
ranging and maintenance studies for methotrexate are needed 51, 52.
Conclusion
In summary, there are several potential reasons why methotrexate is used with such a low 
frequency in the treatment of IBD (table 2). However, given its proven clinical efficacy in 
CD, methotrexate remains an affordable alternative. Methotrexate use should be considered 
for therapy of CD, particularly given the current climate of rising health care costs.
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Medication use in a cohort of 108,518 IBD patients between 1997 and 2009 in the USA. 
Source: IMS Health, LifeLink™ Health Plan Claims Database, From 1997 to 2009. Rx, 
prescription. For methods see 53.
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Study flow of the randomized, double blind, prospective trial investigating the efficacy of 
methotrexate in induction and maintenance of steroid free remission in ulcerative colitis 
(MEthotrexate Response In Treatment of UC - MERIT-UC).
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Randomized, investigator-blind study investigating the therapeutic efficacy of methotrexate 
25 mg/week given initially intravenously (iv) for 3 months and then orally 3 for 3 months 
compared to azathioprine 2mg/kg bodyweight/day 32.
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Patient preference for administration of hormonal therapy with similar efficacy and 
tolerability of oral or subcutaneous application. The majority of 208 breast cancer patients 
preferred hormone therapy via daily tablets rather than monthly injections 47.
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Table 1
Cochrane analyses of the efficacy of azathioprine (AZA) / 6-mercaptopurine (6-MP) and methotrexate (MTX). 
NNT: Number needed to treat, NNH: Number needed to harm. NR: not reported. 27–30
Number of trials Patients (drug+placebo) NNT NNH
AZA/6-MP Induction 8 425 5 14
MTX Induction 1 141 5 NR
AZA/6-MP Maintenance 7/1 550 6/4 20
MTX Maintenance 3 98 4 NR
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Table 2
Potential factors influencing the use of methotrexate compared to other therapies in patients with IBD.
Positive Probably neither positive nor negative Negative
• Maintenance of remission 
in CD
• Effective to induce remission (with steroids) in CD • Prior negative studies in UC
• Inexpensive • Toxicity (liver, lung, hematopoetic system) • Needs to be injected
• No increased lymphoma 
risk
• Drug monitoring: No test to predict toxicity or 
therapeutic levels
• Not to be used in case of anticipated pregnancy
• Fewer studies • Second/Third line recommendation (ECCO-
guidelines)
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